Resverlogix is uniquely positioned in key markets with significant unmet medical needs. Our technology platform encompasses the following programs: NexVas Plaque Regression, Autoimmune Drug Development, and NexVas Alzheimer's Disease.
Technology Platform
NexVas Plaque Regression
Novel small molecules that enhance ApoA-I for atherosclerosis plaque regression.
Autoimmune Drug Development Program
Our objective is to discover and develop a new oral therapy for the treatment of autoimmune diseases by targeting two clinically validated cytokine mediators, IL-6 and IL-17.
Novel small molecules that enhance ApoA-I for favourable effects on cognition, memory and protection against dementia.
Novel small molecules that enhance ApoA-I for favourable effects on cognition, memory and protection against dementia.
Novel small molecules that enhance ApoA-I for favourable effects on cognition, memory and protection against dementia.
Novel small molecules that enhance ApoA-I for favourable effects on cognition, memory and protection against dementia.
